FDA removes partial hold on Telcyta clinical development
FDA removes partial hold on Telcyta clinical development
PALO ALTO, CaliforniaTelik, Inc. has announced that the FDA has removed the partial hold on Telcyta (canfosfamide HCl) clinical trials. This action follows a complete review of Telcyta data by the agency and permits the resumption of Telcyta clinical development. Telcyta is a tumor-activated small-molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small-cell lung cancer. FDA placed the hold on development after phase III data showed lower median survival for women with advanced ovarian cancer receiving Telcyta vs standard chemotherapy.
Articles in this issue
MT103, BiTE antibody, enters phase II testing for ALL
Sides dig in as ESA policy debate heats up
Ixempra gets ok for resistant breast cancer
ASCO adds Oncotype DX to marker guideline
Dr. Norton hopes to weed 'molecular' tumor garden
Accelerated approval for Tasigna
Oxidative stress inducer ups survival in advanced melanoma
FDA removes partial hold on Telcyta clinical development
Should all HER2+ pts receive adjuvant trastuzumab?
R-CHOP is standard of care for advanced DLBCL patients
FDA oks Velcade for patients with renal dysfunction
Phase II trials planned for oral methylnaltrexone for chronic pain
GSK and Synta announce STA-4783 collaboration
2007: A tumultuous year for erythropoietic-stimulating agents
MB07133 gets orphan drug status
Recent Videos
Related Content
